These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1249 related articles for article (PubMed ID: 27920219)

  • 1. The Proprotein Convertases in Hypercholesterolemia and Cardiovascular Diseases: Emphasis on Proprotein Convertase Subtilisin/Kexin 9.
    Seidah NG; Abifadel M; Prost S; Boileau C; Prat A
    Pharmacol Rev; 2017 Jan; 69(1):33-52. PubMed ID: 27920219
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The proprotein convertases are potential targets in the treatment of dyslipidemia.
    Seidah NG; Prat A
    J Mol Med (Berl); 2007 Jul; 85(7):685-96. PubMed ID: 17351764
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel strategies to target proprotein convertase subtilisin kexin 9: beyond monoclonal antibodies.
    Seidah NG; Prat A; Pirillo A; Catapano AL; Norata GD
    Cardiovasc Res; 2019 Mar; 115(3):510-518. PubMed ID: 30629143
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biology of proprotein convertase subtilisin kexin 9: beyond low-density lipoprotein cholesterol lowering.
    Norata GD; Tavori H; Pirillo A; Fazio S; Catapano AL
    Cardiovasc Res; 2016 Oct; 112(1):429-42. PubMed ID: 27496869
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The efficacy of anti-PCSK9 antibodies: Results from recent trials.
    Gouni-Berthold I
    Atheroscler Suppl; 2017 Nov; 30():9-18. PubMed ID: 29096867
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition and the Future of Lipid Lowering Therapy.
    Joseph L; Robinson JG
    Prog Cardiovasc Dis; 2015; 58(1):19-31. PubMed ID: 25936907
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons.
    Yadav K; Sharma M; Ferdinand KC
    Nutr Metab Cardiovasc Dis; 2016 Oct; 26(10):853-62. PubMed ID: 27352986
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The next generation of novel low-density lipoprotein cholesterol-lowering agents: proprotein convertase subtilisin/kexin 9 inhibitors.
    Shen L; Peng H; Xu D; Zhao S
    Pharmacol Res; 2013 Jul; 73():27-34. PubMed ID: 23578522
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis.
    Urban D; Pöss J; Böhm M; Laufs U
    J Am Coll Cardiol; 2013 Oct; 62(16):1401-8. PubMed ID: 23973703
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Proprotein Convertase Subtilisin Kexin Type 9 Inhibition for Autosomal Recessive Hypercholesterolemia-Brief Report.
    Thedrez A; Sjouke B; Passard M; Prampart-Fauvet S; Guédon A; Croyal M; Dallinga-Thie G; Peter J; Blom D; Ciccarese M; Cefalù AB; Pisciotta L; Santos RD; Averna M; Raal F; Pintus P; Cossu M; Hovingh K; Lambert G
    Arterioscler Thromb Vasc Biol; 2016 Aug; 36(8):1647-50. PubMed ID: 27079874
    [TBL] [Abstract][Full Text] [Related]  

  • 11. From lipoprotein apheresis to proprotein convertase subtilisin/kexin type 9 inhibitors: Impact on low-density lipoprotein cholesterol and C-reactive protein levels in cardiovascular disease patients.
    Zenti MG; Altomari A; Lupo MG; Botta M; Bonora E; Corsini A; Ruscica M; Ferri N
    Eur J Prev Cardiol; 2018 Nov; 25(17):1843-1851. PubMed ID: 30058841
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PCSK9 and Hypercholesterolemia: Therapeutic Approach.
    Obradovic M; Zaric B; Sudar-Milovanovic E; Ilincic B; Stokic E; Perovic M; Isenovic ER
    Curr Drug Targets; 2018; 19(9):1058-1067. PubMed ID: 29210646
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proprotein convertase subtilisin/kexin type 9 inhibition: a new therapeutic mechanism for reducing cardiovascular disease risk.
    Bergeron N; Phan BA; Ding Y; Fong A; Krauss RM
    Circulation; 2015 Oct; 132(17):1648-66. PubMed ID: 26503748
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors: Shaping the future after the further cardiovascular outcomes research with PCSK9 inhibition in subjects with elevated risk (FOURIER) trial.
    Katsiki N; Athyros VG; Mikhailidis DP; Mantzoros C
    Metabolism; 2017 Sep; 74():43-46. PubMed ID: 28477848
    [No Abstract]   [Full Text] [Related]  

  • 15. An update on the clinical development of proprotein convertase subtilisin kexin 9 inhibitors, novel therapeutic agents for lowering low-density lipoprotein cholesterol.
    Ling H; Burns TL; Hilleman DE
    Cardiovasc Ther; 2014 Apr; 32(2):82-8. PubMed ID: 24354905
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The multifaceted proprotein convertases: their unique, redundant, complementary, and opposite functions.
    Seidah NG; Sadr MS; Chrétien M; Mbikay M
    J Biol Chem; 2013 Jul; 288(30):21473-81. PubMed ID: 23775089
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PCSK9 antibodies: A new class of lipid-lowering drugs.
    Gouni-Berthold I
    Atheroscler Suppl; 2015 May; 18():21-7. PubMed ID: 25936300
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Physiology and role of PCSK9 in vascular disease: Potential impact of localized PCSK9 in vascular wall.
    Guo Y; Yan B; Gui Y; Tang Z; Tai S; Zhou S; Zheng XL
    J Cell Physiol; 2021 Apr; 236(4):2333-2351. PubMed ID: 32875580
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PCSK9 inhibition in patients with hypercholesterolemia.
    Desai NR; Sabatine MS
    Trends Cardiovasc Med; 2015 Oct; 25(7):567-74. PubMed ID: 25771732
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proprotein convertase subtilisin/kexin type 9 (PCSK9): from structure-function relation to therapeutic inhibition.
    Tibolla G; Norata GD; Artali R; Meneghetti F; Catapano AL
    Nutr Metab Cardiovasc Dis; 2011 Nov; 21(11):835-43. PubMed ID: 21943799
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 63.